The UK rolls out the welcome mat to MGC Pharma’s epilepsy treatment
Health & Biotech
Special Report: MCG Pharma can now legally import its cannabis-based CannEpil treatment into the UK, laying the foundation for wider distribution.
The European-focused bio-pharma company says it has received a Controlled Drug Import License Permit, meaning it can expand its distribution within the UK’s medicinal cannabis market via its partner Lenis, a European pharmaceutical company.
MGC Pharmaceuticals (ASX:MXC) also told investors this morning it had received purchase orders for CannEpil in Australia and the UK through its licensed distribution partners, with delivery scheduled for this month.
CannEpil is an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, which accounts for about 30 per cent of all epilepsy cases.
Epilepsy affects around one in every 100 people in the UK, with more than 500,000 people diagnosed.
MGC also says it is progressing with negotiations with additional Australian and UK distribution partners to further expand distribution both CannEpil and CogniCann, its cannabis treatment for patients aged 65 and over with mild dementia and Alzheimer’s.
Recruitment for its Phase IIb clinical trial for CogniCann is currently underway with the University of Notre Dame in Western Australia.
MGC managing director Roby Zomer said receipt of the permit will significantly expand the potential distribution of CannEpil.
“With first purchase orders from the UK and Australian licensed distribution partners already received, and new distribution deals expected to be signed in the coming weeks, our expanded distribution in Australia, Europe and the UK will mean we will be able to provide more patients in need with access to CannEpil and our other investigational medicinal products (IMPs).”